A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of GSBR-1290 in Healthy Volunteers
Latest Information Update: 02 Aug 2023
At a glance
- Drugs Aleniglipron (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors Avance Clinical Pty Ltd; Gasherbrum Bio
Most Recent Events
- 26 Jun 2023 Results assessing safety, tolerability, and pharmacokinetics (PK) of a single dose of GSBR-1290 in Healthy Volunteers presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
- 07 Jun 2023 According to a Structure Therapeutics media release, data from this study will be presented at the upcoming American Diabetes Association (ADA) 83rd Scientific Sessions taking place June 23-26, 2023, in San Diego, CA.
- 01 Aug 2022 Results published in the Structure Therapeutics Media Release.